Glenmark Pharmaceuticals today said it had received approval from the US health regulator to market generic Nizatidine capsules, used for treating ulcers, in the American market.
Glenmark Generics, the company's subsidiary, has received final approval from the United States Food and Drug Administration (USFDA) for Nizatidine capsules, Glenmark Pharmaceuticals said in a filing to the Bombay Stock Exchange (BSE).
The company will commence marketing immediately, it added.
"Nizatidine capsules are a generic version of Axid by SmithKline Beecham Corporation and are indicated for up to eight weeks for the treatment of active duodenal ulcers," Glenmark said.
Shares of Glenmark Pharmaceuticals were being quoted at Rs 326 apiece in afternoon trade on the BSE today, down 1.69% from their previous close.
